Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.40 per share
-
Shares outstanding
-
23.6M
-
Number of holders
-
58
-
Total 13F shares, excl. options
-
45.5M
-
Shares change
-
+554K
-
Total reported value, excl. options
-
$190M
-
Value change
-
+$1.66M
-
Put/Call ratio
-
0
-
Number of buys
-
23
-
Number of sells
-
-37
-
Price
-
$4.17
Significant Holders of Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share (AUTL) as of Q1 2022
77 filings reported holding AUTL - Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share as of Q1 2022.
Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share (AUTL) has 58 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.5M shares
.
Largest 10 shareholders include Blackstone Inc. (18M shares), Nantahala Capital Management, LLC (4.35M shares), Frazier Life Sciences Management, L.P. (3.75M shares), CITADEL ADVISORS LLC (3.51M shares), TFG Asset Management GP Ltd (2.83M shares), SCHRODER INVESTMENT MANAGEMENT GROUP (1.67M shares), FMR LLC (1.64M shares), Pendal Group Ltd (1.38M shares), Capital World Investors (1.06M shares), and JPMORGAN CHASE & CO (800K shares).
This table shows the top 58 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.